Skip to main content

PHAR · Pharming Group N.V. · Financials

Track PHAR — free
$11.06 -0.16 (-1.38%)
Market Cap
$793.42M
Shares
70.78M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$376.13M +26.6%
FY2025 Revenue FY2019–FY2025
Net Income
$2.85M +124.1%
FY2025 Net Income FY2023–FY2025
Gross Margin
87.9% -0.2pp
FY2025 Gross Margin FY2019–FY2025
Operating Margin
6.87% +9.8pp
FY2025 Operating Margin FY2019–FY2025
Diluted EPS
$0.00 +122.2%
FY2025 Diluted EPS FY2019–FY2025
Operating Cash Flow
$54.71M +3147.8%
FY2025 Operating Cash Flow FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
USD/shares $0.00 -$0.02 -$0.02 $0.02 $0.03 $0.06 $0.07
USD/shares $0.00 -$0.02 -$0.02 $0.02 $0.02 $0.06 $0.06
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
United States $361,746,000 $287,149,000 $239,107,000 $200,082,000 $193,419,000 $202,684,000 $182,294,000
Europe and Rest of the World $14,388,000 $10,051,000 $6,209,000 $5,540,000 $4,933,000
Rest of the World Excluding US and Europe $1,258,000 $1,447,000
Europe $8,232,000 $5,648,000
Key facts CIK 1828316 CUSIP 71716E105 13F (30d) 4 filings 3 filers Visit website Investor relations